共 50 条
- [1] Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy[J]. CLINICAL CANCER RESEARCH, 2011, 17 (15) : 5179 - 5187Lee, Young JooYoon, Kyong-AhHan, Ji-YounKim, Heung TaeYun, TakLee, Geon KookKim, Hyae YoungLee, Jin Soo
- [2] Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers[J]. LUNG CANCER, 2005, 49 : S38 - S38Lee, DHan, JLee, EKim, HKim, HHong, ELee, J
- [3] Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers[J]. CLINICAL CANCER RESEARCH, 2005, 11 (08) : 3032 - 3037Lee, DHHan, JYLee, HGLee, JJLee, EKKim, HYKim, HKHong, EKLee, JS
- [4] Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (12) : 2009 - 2016Lee, YoungjooKim, Sun HyeHan, Ji-YounKim, Heung TaeYun, TakLee, Jin Soo
- [5] Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy[J]. Journal of Cancer Research and Clinical Oncology, 2012, 138 : 2009 - 2016Youngjoo LeeSun Hye KimJi-Youn HanHeung Tae KimTak YunJin Soo Lee
- [6] Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma[J]. THERANOSTICS, 2021, 11 (01): : 257 - 267Jiang, TaoJiang, LiyanDong, XiaorongGu, KangshengPan, YueyinShi, QinZhang, GuojunWang, HuijuanZhang, XiaochunYang, NongLi, YupingXiong, JianpingYi, TienanPeng, MinSong, YongFan, YunCui, JiuweiChen, GongyanTan, WeiZang, AiminGuo, QisenZhao, GuangqiangWang, ZipingHe, JianxingYao, WenxiuWu, XiaohongChen, KaiHu, XiaohuaHu, ChunhongYue, LuJiang, DaWang, GuangfaLiu, JunfengYu, GuohuaLi, JunlingZhang, HenghuiWu, LihongFang, LuLiang, DandanZhao, YiZhao, WeihongXie, WenminRen, ShengxiangZhou, Caicun
- [7] A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung[J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S283 - S284Lee, Jin S.Park, KeunchilKim, Sang-WeLee, Dae HoKim, Heung TaeHan, Ji-YounYun, TakAhn, Myung-JuAhn, Jin SeokSuh, CheolwonLee, Jung-ShinHan, Jong HeeYu, Sun YoungLee, Jae WonJo, SookJung
- [8] LAPATINIB WITH CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED NSCLC IN NEVER SMOKERS OR SELDOM SMOKERS[J]. LUNG CANCER, 2009, 64 : S55 - S56Pandey, R.Dey, S.Mukhopadhyay, A.
- [9] Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)Coco, SimonaAlama, AngelaVanni, IreneFontana, VincenzoGenova, CarloDal Bello, Maria GiovannaTruini, AnnaRijavec, ErikaBiello, FedericaSini, ClaudioBurrafato, GiovanniMaggioni, ClaudiaBarletta, GiuliaGrossi, Francesco
- [10] Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)[J]. ANNALS OF ONCOLOGY, 2016, 27Wang, J.Cheng, Y.Wu, Y-L.An, T.Gao, H.Wang, K.Zhou, Q.Hu, Y.Song, Y.Ding, C.Ye, X.Peng, F.Liang, L.Hu, Y.Huang, C.Zhou, C.Shi, Y-K.Zhang, L.Gu, Y.